{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.80","upperLimit":"25000","value":"1302.41"},{"groupId":"OG001","lowerLimit":"557.97","upperLimit":"6177.17","value":"1126.52"}]}],"title":"Ferritin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.20","upperLimit":"100.00","value":"18.72"},{"groupId":"OG001","lowerLimit":"6.23","upperLimit":"90.34","value":"23.95"}]}],"title":"IL-2 R alpha"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"230.12","upperLimit":"60593.2467","value":"1252.07"},{"groupId":"OG001","lowerLimit":"218.96","upperLimit":"1678.80","value":"1033.85"}]}],"title":"ICAM-1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.69","upperLimit":"100.00","value":"18.71"},{"groupId":"OG001","lowerLimit":"5.86","upperLimit":"36.47","value":"13.84"}]}],"title":"Perforin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"503.80","upperLimit":"156061.4308","value":"1843.57"},{"groupId":"OG001","lowerLimit":"416.85","upperLimit":"3239.41","value":"1829.69"}]}],"title":"VCAM-1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Peak was defined as the maximum post-baseline level of the cytokine.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"},{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG001","title":"Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants from the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 4","title":"Peak Serum Levels of Ferritin, Interleukin-2 Receptor Alpha (IL-2Rα), Intercellular Adhesion Molecule-1 (ICAM-1), Perforin, Vascular Cell Adhesion Molecule-1 (VCAM-1) in Blood","type":"SECONDARY","unitOfMeasure":"ng/mL"}